California State Teachers Retirement System Cuts Position in Tetraphase Pharmaceuticals Inc. (TTPH)
California State Teachers Retirement System cut its position in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 0.3% during the second quarter, Holdings Channel reports. The firm owned 76,320 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. California State Teachers Retirement System owned about 0.21% of Tetraphase Pharmaceuticals worth $328,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. Bellevue Group AG purchased a new stake in shares of Tetraphase Pharmaceuticals during the first quarter worth approximately $102,000. Nisa Investment Advisors LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 2,618.8% in the second quarter. Nisa Investment Advisors LLC now owns 43,500 shares of the biopharmaceutical company’s stock worth $187,000 after buying an additional 41,900 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth approximately $257,000. Pacad Investment Ltd. boosted its stake in shares of Tetraphase Pharmaceuticals by 144.5% in the first quarter. Pacad Investment Ltd. now owns 62,443 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 36,900 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 0.7% in the first quarter. Geode Capital Management LLC now owns 233,255 shares of the biopharmaceutical company’s stock worth $1,079,000 after buying an additional 1,713 shares during the period. 59.38% of the stock is owned by hedge funds and other institutional investors.
Shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) traded up 2.1121% during mid-day trading on Monday, reaching $3.4616. The company had a trading volume of 127,610 shares. The company’s market capitalization is $127.03 million. Tetraphase Pharmaceuticals Inc. has a one year low of $3.12 and a one year high of $12.45. The company has a 50 day moving average price of $3.77 and a 200 day moving average price of $4.25.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.01. The business had revenue of $1.20 million for the quarter, compared to the consensus estimate of $2.05 million. Tetraphase Pharmaceuticals had a negative net margin of 821.25% and a negative return on equity of 35.43%. The company’s revenue for the quarter was down 63.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.72) EPS. On average, analysts anticipate that Tetraphase Pharmaceuticals Inc. will post ($1.98) EPS for the current year.
TTPH has been the subject of a number of research reports. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research note on Wednesday, July 6th. Wedbush restated a “neutral” rating and issued a $4.00 target price on shares of Tetraphase Pharmaceuticals in a report on Friday, August 5th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $9.15.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.
Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH).
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.